ITRMF — Iterum Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Iterum Names Christine Coyne As Chief Commercial Officer To Lead Orlynvah™ Launch And Commercial Growth
Brief: Iterum Therapeutics PLC Preparing For Potential Launch Of Orlynvah(Tm) By Q4 2025
Iterum Therapeutics PLC expected to post a loss of 14 cents a share - Earnings Preview
Brief: Iterum Therapeutics Announces $5 Million Registered Direct Offering Of Ordinary Shares
Brief: Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $150 Million
Iterum Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary
Iterum Therapeutics PLC expected to post a loss of 21 cents a share - Earnings Preview
Brief: Iterum Therapeutics Regains Full Nasdaq Compliance
Iterum Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary
Iterum Therapeutics PLC expected to post a loss of 20 cents a share - Earnings Preview
Brief: Iterum Therapeutics defers milestone payment to Pfizer
Brief: Iterum Therapeutics To Renew Efforts For Strategic Transaction Involving ORLYNVAH
US FDA approves Iterum's treatment for urinary infection (updated)
Brief: FDA Approves Iterum Therapeutics' Orlynvah For Treatment Of Uncomplicated Urinary Tract Infections - Website
FDA approves Iterum's treatment for urinary infection
What to Watch in the Day Ahead - Friday, October 25
Brief: Iterum Therapeutics Got Delisting Determination Letter Advising That Nasdaq Determined Co Did Not Meet Terms Of Extension For Compliance
Brief: Iterum Therapeutics PLC EGM Adjourned Until Oct 8, 2024- Filing
Iterum Therapeutics PLC reports results for the quarter ended in June - Earnings Summary